Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
Filing tables
Filing exhibits
OKYO similar filings
Filing view
External links
Exhibit 15.2
Consent of Independent Registered Public Accounting Firm
The Board of Directors of OKYO Pharma Ltd:
We consent to the incorporation by reference of our report dated August 14, 2023 with respect to the consolidated balance sheet for the year ended March 31, 2023 and the related consolidated statement of operations and comprehensive loss, cash flows and shareholders’ equity for the period ended March 31, 2023, and the related notes, for OKYO Pharma Ltd, which report appears in the March 31, 2023 annual report on Form 20-F.
/s/ PKF Littlejohn LLP.
PKF Littlejohn LLP
London
August 14, 2023